CONTEXT: Fatigue is a common problem in oncology patients. Less is known about decrements in energy levels and the mechanisms that underlie both fatigue and energy. OBJECTIVES: In patients with breast cancer, variations in neurotransmitter genes between lower and higher fatigue latent classes and between the higher and lower energy latent classes were evaluated. METHODS: Patients completed assessments before and monthly for six months after surgery. Growth mixture modeling was used to identify distinct latent classes for fatigue severity and energy levels. Thirty candidate genes involved in various aspects of neurotransmission were evaluated. RESULTS: Eleven single-nucleotide polymorphisms or haplotypes (i.e., ADRB2 rs1042718, BDNF rs6265, COMT rs9332377, CYP3A4 rs4646437, GALR1 rs949060, GCH1 rs3783642, NOS1 rs9658498, NOS1 rs2293052, NPY1R Haplotype A04, SLC6A2 rs17841327, and 5HTTLPR + rs25531 in SLC6A4) were associated with latent class membership for fatigue. Seven single-nucleotide polymorphisms or haplotypes (i.e., NOS1 rs471871, SLC6A1 rs2675163, SLC6A1 Haplotype D01, SLC6A2 rs36027, SLC6A3 rs37022, SLC6A4 rs2020942, and TAC1 rs2072100) were associated with latent class membership for energy. Three of 13 genes (i.e., NOS1, SLC6A2, and SLC6A4) were associated with latent class membership for both fatigue and energy. CONCLUSIONS: Molecular findings support the hypothesis that fatigue and energy are distinct, yet related symptoms. Results suggest that a large number of neurotransmitters play a role in the development and maintenance of fatigue and energy levels in breast cancer patients.
CONTEXT: Fatigue is a common problem in oncology patients. Less is known about decrements in energy levels and the mechanisms that underlie both fatigue and energy. OBJECTIVES: In patients with breast cancer, variations in neurotransmitter genes between lower and higher fatigue latent classes and between the higher and lower energy latent classes were evaluated. METHODS:Patients completed assessments before and monthly for six months after surgery. Growth mixture modeling was used to identify distinct latent classes for fatigue severity and energy levels. Thirty candidate genes involved in various aspects of neurotransmission were evaluated. RESULTS: Eleven single-nucleotide polymorphisms or haplotypes (i.e., ADRB2rs1042718, BDNFrs6265, COMTrs9332377, CYP3A4rs4646437, GALR1rs949060, GCH1rs3783642, NOS1rs9658498, NOS1rs2293052, NPY1R Haplotype A04, SLC6A2rs17841327, and 5HTTLPR + rs25531 in SLC6A4) were associated with latent class membership for fatigue. Seven single-nucleotide polymorphisms or haplotypes (i.e., NOS1rs471871, SLC6A1rs2675163, SLC6A1 Haplotype D01, SLC6A2rs36027, SLC6A3rs37022, SLC6A4rs2020942, and TAC1rs2072100) were associated with latent class membership for energy. Three of 13 genes (i.e., NOS1, SLC6A2, and SLC6A4) were associated with latent class membership for both fatigue and energy. CONCLUSIONS: Molecular findings support the hypothesis that fatigue and energy are distinct, yet related symptoms. Results suggest that a large number of neurotransmitters play a role in the development and maintenance of fatigue and energy levels in breast cancerpatients.
Authors: Monika Althaus; Yvonne Groen; Albertus A Wijers; Ruud B Minderaa; Ido P Kema; Janneke D A Dijck; Pieter J Hoekstra Journal: Biol Psychol Date: 2010-05-05 Impact factor: 3.251
Authors: A Terracciano; B Martin; D Ansari; T Tanaka; L Ferrucci; S Maudsley; M P Mattson; P T Costa Journal: Genes Brain Behav Date: 2010-03-22 Impact factor: 3.449
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Christina Van Onselen; Bradley E Aouizerat; Laura B Dunn; Steven M Paul; Claudia West; Deborah Hamolsky; Kathryn Lee; Michelle Melisko; John Neuhaus; Christine Miaskowski Journal: Breast Date: 2012-08-01 Impact factor: 4.380
Authors: Fay Wright; Laura B Dunn; Steven M Paul; Yvette P Conley; Jon D Levine; Marilyn J Hammer; Bruce A Cooper; Christine Miaskowski; Kord M Kober Journal: Cancer Nurs Date: 2019 Sep/Oct Impact factor: 2.592
Authors: Inger Utne; Borghild Løyland; Ellen Karine Grov; Hege Lund Rasmussen; Ann Helen Torstveit; Bruce A Cooper; Judy Mastick; Melissa Mazor; Melisa Wong; Steven M Paul; Yvette P Conley; Thierry Jahan; Christine Ritchie; Jon D Levine; Christine Miaskowski Journal: Eur J Oncol Nurs Date: 2018-08-22 Impact factor: 2.398
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Melisa L Wong; Steven M Paul; Judy Mastick; Christine Ritchie; Michael A Steinman; Louise C Walter; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-23 Impact factor: 3.612
Authors: Gee Su Yang; Sreelakshmy Kumar; Susan G Dorsey; Angela R Starkweather; Debra Lynch Kelly; Debra E Lyon Journal: Support Care Cancer Date: 2018-10-20 Impact factor: 3.603
Authors: Nathan Ashley Pearson; Elizabeth Tutton; J Martindale; George Strickland; Jean Thompson; Jonathan C Packham; Paul Creamer; Kirstie Haywood Journal: BMJ Open Date: 2022-02-25 Impact factor: 2.692
Authors: Ali Boolani; Karyn M Gallivan; Kristin S Ondrak; Courtney J Christopher; Hector F Castro; Shawn R Campagna; Christopher M Taylor; Meng Luo; Scot E Dowd; Matthew Lee Smith; Lauri O Byerley Journal: Nutrients Date: 2022-01-21 Impact factor: 5.717